AzTrials
AzTrials

Depression, AnxietyNCT05373329

Testing a Digital Health Intervention App for Depression and Anxiety

A study testing Sanvello (app) in people with Depression, Anxiety, run by University of Nevada, Las Vegas at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Although mobile applications ("apps") for mental health are popular and widely available, little is known about how well they actually help people with common mental health symptoms of depression, anxiety, and stress. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Depression, Anxiety
What is being tested?
Sanvello (app)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4,607 participants
Where
1 siteUnited States
Study dates
14 Jun 2021to 4 Feb 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Have a compatible smartphone (Android or Apple)
  • Age 18 or older
  • Ability to read and write English [Justification: (1) limited availability of Sanvello coaches fluent in languages other than English; and (2) use of English language assessments.]
  • Located in the US
  • Clinically significant symptoms of depression and/or anxiety, as evidenced by:
  • Scores of ≥10 on the PHQ-9 depression assessment (Kroenke et al., 2009); and/or
  • Scores of ≥8 on the GAD-7 anxiety assessment (Spitzer et al., 2006)

Who cannot join

  • • Active suicidal ideation
  • History of suicide attempt(s)
  • Current symptoms of:
  • Psychosis
  • Active substance abuse
  • History of provider diagnosis of:
Show all 12Show fewer
  • Bipolar disorder ("manic-depression")
  • Dementia
  • Intellectual disability
  • Currently in or scheduled to initiate individual psychotherapy to avoid treatment interference.
  • Prior use of Sanvello
  • Psychotropic medication permitted if dose was stable over the past 2 weeks

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Nevada Las Vegas

    Las Vegas, Nevada, 89154

Other trials in United States

About this study

Official title: Comparison of a Mobile Digital Health Intervention Versus Waitlist Control for the Treatment of Depression and Anxiety: A Randomized Controlled Trial

Although mobile applications ("apps") for mental health are popular and widely available, little is known about how well they actually help people with common mental health symptoms of depression, anxiety, and stress. We are partnering with a commercially available app to test how well this app helps people's mental health over 8 weeks. Participants will be randomly assigned (like flipping a coin) to two groups: (a) using the app, (b) no app until after 8 weeks. We will ask participants to complete online surveys about their mood and well-being so we can better understand the effects of these different treatments.

Read the detailed description

This research is focused on evaluating mental health outcomes associated with a commercially available programs offered by Sanvello Health compared to a control condition.

Background on the Sanvello program:

Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation. The app also includes features like mood and health tracking to help individuals notice patterns in their moods and adjust their activities to manage their emotions more effectively. Additionally, there is a "hope board" which serves as a place for users to put inspirational quotes, reassuring photos, or save their completed activities to be reminded of their successes in using the app. Finally, the app offers a peer support community, which is a discussion board for users to connect with others going through similar experiences or who share interests. The interventions based on Cognitive-Behavioral Therapy (CBT) include the "Thoughts" tool, which educates users about the effect of thinking errors or "cognitive distortions" on emotions and then prompts users to complete a text-based thought record, identify any cognitive distortions, and then challenge those thoughts (via positive reframe). The "Goals" tool is also based on CBT and allows users to create a list of goals to face their fears (in the case of anxiety) or re-engage with life (for those struggling with depression). The tool helps users to track their tasks and progress. The interventions based on Mindfulness include "Meditations" which provides a suite of activities for users to learn mindfulness, practice deep breathing or body scans, guided relaxation activities, or simply listen to soothing sounds. Sanvello also offers health-behavior tracking which allows users to monitor activities of their choice such as caffeine consumption, exercise, time spent with loved ones, etc. Users can also track their mood state "How are you feeling?". Additionally, users can create and track custom health activities and associate words with their mood from pre-set options such as "stressed" or "happy" or can specify their own words using a hashtag such as "#engaged".

Treatment Groups:

Study participation involves assignment to one of these two groups (app use or waitlist control) and participation in study assessments. The interventions are developed, maintained, and delivered by Sanvello independent of this research study. App use is not prescribed, regulated, or restricted in any way as part of this study; rather, we are interested in collecting app use as outcome data. Primary analyses will be intent-to-treat (i.e., based on group assignment) regardless of app use; app use will also be examined as a covariate during analyses.

Although the app is commercially available, the active condition in this study (app use) require payment for regular users (i.e., those not involved in this study). We hope to incentivize participation by offering the app free to all participants, including waitlist participants (after their 8-week waiting period). Ultimately, there is no way of knowing whether a person chooses to download and use Sanvello or another commercially available digital mental health app during this trial.

Study Procedures:

This is a fully remote study. Participants in the study will be allowed to use the app however they want, in the same way that regular app users can. There is no minimum or maximum "dose" specified.

All research procedures (independent from app use) will be collected and stored in REDCap, a secure web application for building and managing online surveys and databases. This includes the consent information, screening, and assessment procedures. Participant contact data (i.e., email address) will be remotely collected and stored. They will receive a hyperlink directing to download the app once they are deemed eligible. REDCap will send reminders for each assessment timepoint with the survey link to complete the assessment. At no point is direct contact with members of the research team necessary.

Please see the uploaded image of study flow for additional visualization of these procedures ("Sanvello RCT flow"). The study procedures are as follows:

  1. Online recruitment ad with link to landing page
  2. Online ads will indicate that the University of Nevada-Las Vegas and Sanvello are partnering to better understand the effectiveness of mobile apps for mental health. Recruitment from patients seeking care on the Sanvello platform will direct to a similar advertisement. Examples of the advertisements have been uploaded along with this application.
  3. Basic screening and eligibility questions via online survey
  4. Verify age (18 or older)
  5. Verify US location
  6. Verify compatible smartphone use
  7. Potentially eligible participants will be directed to review online consent information
  8. Participants will be asked to complete a consent quiz to ensure they understand the study protocol, consisting of these three true/false questions: i. I am participating in a clinical trial and may be selected to receive the Sanvello app or wait for 8 weeks to receive access to the app. (T) ii. I am a volunteer and can drop out of the study at any time, without penalty. (T) iii. I will be completing questionnaires every 2 weeks and will receive either Amazon gift codes or Visa giftcards as payment for answering questions. (T)
  9. Participants who agree to participate will be directed to complete other screening/eligibility questions (uploaded for review)
  10. Eligible participants are directed to online baseline assessment
  11. We will collect participant email address for future automated assessment invitations (from REDCap) and for issuing incentive payments for completed assessments.
  12. We will assess further eligibility criteria, including the PHQ-9 and GAD-7 (uploaded for review)
  13. Eligible participants will complete online baseline assessment
  14. Participants (up to 375) will be randomized to one of two groups:
  15. Eligible participants will be randomized according to a computer-generated randomization sequence using randomly permuted blocks, allowing for equal allocation of participants to treatment groups (n = 125 assigned to each treatment group). The randomization sequence will be created by the graduate research assistant using R statistical software. Randomization assignment will be concealed until after entry criteria are confirmed.
  16. Participants in the trial will be randomly assigned to either a) receive the self-guided app intervention immediately, or b) receive the self-guided intervention after an 8-week waiting period (waitlist control group). All groups will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
  17. Unique study IDs are automatically assigned to each participant at this point. This study ID will link their assessment data and their Sanvello app data.
  18. Participants will receive an electronic invitation (link) to either a) download the self-guided app; or b) notifications of waitlist condition. These invitations will contain unique participant identifiers to link to their Sanvello app data
  19. All participants receive biweekly notifications for assessments (weeks 2, 4, 6, and 8). These are sent automatically from REDCap to the email address that the participant provided at baseline.
  20. Participants will have one week to complete the schedule assessment at each timepoint before the assessment window closes.
  21. At the end of 8-week study participation, individuals assigned to the waitlist control will receive a promo code for 8 weeks of complimentary Sanvello use. This code will include the unique participant ID, which will be used to track Sanvello app use. This is provided as a benefit of participation. No further data will be collected after the 8-week control condition timeframe ends.
  22. The graduate research assistant will send participant incentive (for completed assessment) via email on a biweekly basis based on assessment completion records in REDCap.
  23. At the end of study data collection, the PI will destroy the record of participant email addresses as the only identifying link to study records.
  24. After data collection has stopped, all incentives have been issued, and the link to the identifier (i.e., email addresses) has been destroyed, Sanvello will send a deidentified dataset to the PI using their secure data transfer system.
  25. This dataset will include unique participant IDs and deidentified usage analytics, including number of app sessions, number of days the intervention was used, time to last use, days of app use, and completion of app tasks. These data are routinely collected from all users per Sanvello's Privacy Policy.

Dr. Renn (PI) and Dr. Raue (Co-I) will meet with the Sanvello team at least twice during data collection to discuss recruitment and study progress. The Sanvello team consists of the company's Chief Medical Officer and Chief Technology Officer, in addition to a project manager and other staff as necessary.

Study Assessments:

For this study, participants will complete a screener to determine potential eligibility, delivered as an online questionnaire., details about their smartphone use, and psychopathology for study eligibility (i.e. a self-report measure of depression (Patient Health Questionnaire (PHQ)-8 score ≥10) and a self-report measure of anxiety (Generalized Anxiety Disorder (GAD) 7-item Scale score ≥8)), in addition to questions about diagnoses and mental health treatment that would render them ineligible.

Following the screener, individuals who are eligible for study participation will be provided the online consent form. Individuals who consent to the study will then be invited to complete the baseline assessment and randomized into the longitudinal trial.

Eligible individuals will be asked to provide their contact (email) and demographic information.

Participants completing the longitudinal study will complete follow-up assessments via online questionnaires at Weeks 2, 4, 6, and 8.

Being tested
Sanvello (app)
Medical subject headings
Depression, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sanvello (app)Device

    Also called self-guided app; Sanvello Premium

    Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.

Study groups in NCT05373329
Study groupRoleWhat they receive
self-guided app useExperimentalParticipants receive the self-guided app intervention immediately. All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
Receives: Device: Sanvello (app)
waitlist controlNo interventionParticipants receive the self-guided intervention after an 8-week waiting period (waitlist control group). All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Depression scores on the Patient Health Questionnaire-9 (PHQ-9) at end of treatment

    Participants self-reported depression symptoms. Scores range from 0 to 27 where higher scores indicate poorer outcomes (more severe depression).

    Measured: 8 weeks

  2. Anxiety scores from the General Anxiety Disorder-7 (GAD-7) at the end of treatment

    Participants self-reported anxiety symptoms. Scores range from 0 to 21 where higher scores indicate poorer outcomes (i.e., more severe anxiety).

    Measured: 8 weeks

Secondary outcomes (1)
  1. Health-related quality of life scores from The Patient Reported Outcomes Measurement Information System (PROMIS) Global Health measure at the end of treatment

    Participants self-reported their global physical, mental, and social health-related quality of life (H-RQoL). Higher T-scores indicate better outcomes.

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2022
  2. Study start14 Jun 2021
  3. Primary completion4 Feb 2022
  4. Study completion4 Feb 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
4,607 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05373329
Sponsor's protocol ID
1691460
Status last verified
May 2023
First submitted
22 Jun 2021
Last updated
10 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Renn BN, Walker TJ, Edds B, Roots M, Raue PJ. Naturalistic use of a digital mental health intervention for depression and anxiety: A randomized clinical trial. J Affect Disord. 2025 Jan 1;368:429-438. doi: 10.1016/j.jad.2024.09.104. Epub 2024 Sep 17.

    PubMed 39299591

Questions about this trial

What is this clinical trial studying?

A study testing Sanvello (app) in people with Depression, Anxiety, run by University of Nevada, Las Vegas at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Depression scores on the Patient Health Questionnaire-9 (PHQ-9) at end of treatment (time frame: 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05373329, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in